H. Park

机构：Dana-Farber Cancer Institute

发表论文 9 篇 · 总被引 39 次 · h-index 2

代表论文

LBA55 Primary analysis of a phase II single-arm trial of trastuzumab deruxtecan (T-DXd) in western patients (Pts) with HER2-positive (HER2+) unresectable or metastatic gastric or gastroesophageal junction (GEJ) cancer who progressed on or after a trastuzumab-containing regimen (2021 · Annals of Oncology · 被引 28)
916O Preliminary phase I results of INCB161734, a novel oral KRAS G12D inhibitor, in patients with advanced or metastatic solid tumors (2025 · Annals of Oncology · 被引 10)
Nivolumab combination therapies in patients with advanced gastric and gastroesophageal junction cancer: the phase II FRACTION gastric cancer study (2025 · ESMO Open · 被引 1)
Additional file 1 of Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention (‘REVITALIZE’) to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol (2026 · Figshare)
Additional file 1 of Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention (‘REVITALIZE’) to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol (2026 · Figshare)
Randomized clinical trial of an Acceptance and Commitment Therapy telehealth intervention (‘REVITALIZE’) to reduce fatigue interference in women with advanced ovarian cancer on PARP inhibitors: study protocol (2026 · BMC Cancer)